USD 5 million to speed ASPIVIX entry on European and US Markets
Summary
This funding round will accelerate market access in Europe and US, and finance clinical activities in the US, while the EUREKA EUROSTARS grant will fuel R&Ds activities to expand product offering.ASPIVIX, a Swiss medtech startup focused on innovations in womens healthcare and the maker of the new generation of non-traumatic cervix stabilizer CAREVIX, announced today that it has raised $5 million in a Series A+ funding round. explained Julien Finci, co- founder, and CTO.ASPIVIXs vision is to empower women with gentler and safer gynecological procedures through clinically proven technologies. The trust from our existing and new investors is a great motivation to realize our vision in womens health and make a difference for millions of women worldwide co- founder and CEO Mathieu Horras added.We are very impressed with the excellent clinical outcomes ASPIVIX has demonstrated with CAREVIX in gynecological procedures like intra-uterine device (IUD) insertion. adds Pascal Winnen, CEO of HEMEX AG and new Board Member at Aspivix. "We believe that the significant reduction in pain and bleeding, will allow many more women to choose this safe and efficacious method of contraception.